find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
351
Clinical Trials
ES-SCLC
Phase III
Closed to Enrollment
nct/study# 5468489 / HLX-10-005-SCL301-E
A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin- Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)
Learn More
RRFL
1b/3
Enrolling
nct/study# 4224493 / EZH-302 / 245067
SYMPHONY-1: A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Learn More
NSCLC
Phase III
Closed to Enrollment
nct/study# 5555732 / DS1062-A-U303
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung07)
Learn More
NSCLC
Phase III
Enrolling
nct/study# 5215340 / DS1062-A-U304
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)
Learn More
RRMM
Observational Study
Closed to Enrollment
nct/study# N/A / OBS16577
A non-interventional, multinational, observational study with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM)
Learn More
MRD
Observational Study
Enrolling
we are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.